Puma Biotechnology Free Cash Flow (FCF) History (PBYI)

Puma Biotechnology reported $41.7M in free cash flow for fiscal 2025, an increase of 7.38% from the previous fiscal year, with a free cash flow margin of 18.27%.

View full Puma Biotechnology company overview

Puma Biotechnology free cash flow by year

Puma Biotechnology annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31$41.7M$2.9M+7.38%+18.27%
20242024-12-31$38.9M$12.0M+44.64%+16.86%
20232023-12-31$26.9M$42.7M+11.40%
20222022-12-31−$15.8M−$36.5M−6.94%
20212021-12-31$20.6M$19.9M+2740.44%+8.16%
20202020-12-31$727,000−$21.3M−96.71%+0.32%
20192019-12-31$22.1M$46.6M+8.11%
20182018-12-31−$24.5M$148.4M−9.78%
20172017-12-31−$172.9M−$26.9M−624.53%
20162016-12-31−$146.0M$9.5M
20152015-12-31−$155.5M−$77.2M
20142014-12-31−$78.3M−$22.6M
20132013-12-31−$55.7M−$53.6M
20112011-12-31−$2.1M

Puma Biotechnology free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from $727,000 to $41.7M, a compound annual growth rate of 124.79%. Puma Biotechnology's latest reported quarter, Q2 2026, generated $1.6M in free cash flow, a decrease of 88.45% year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Puma Biotechnology filings at SEC.gov ↗